In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate

Sonzini, Silvia; Caputo, Fanny; Méhn, Dóra; Calzolai, Luigi; Borgos, Sven Even F.; Hyldbakk, Astrid; Treacher, Kevin; Liu, Weimin; Jackman, Mark; Mahmoudi, Najet; Lawrence, M. Jayne; Patterson, Claire; Owen, David J.; Akhtar, Nadim

doi:10.1016/j.ijpharm.2023.122905

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article3

Book1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Dendrimer nanoplatforms for oral drug delivery applications

Kim,

2024

J. Pharm. Investig.

View full text Add to dashboard Cite

Dendrimer nanoplatforms for oral drug delivery applications

Kim,

2024

J. Pharm. Investig.

View full text Add to dashboard Cite

Bioinspired nanomaterials: From synthesis to applications

Ahmed,

Hossain,

Mobarak

et al. 2024

Comprehensive Materials Processing

View full text Add to dashboard Cite

How Dendrimers Impact Fibrin Clot Formation, Structure, and Properties

Mina,

Guido,

Prezoto

et al. 2024

ACS Omega

View full text Add to dashboard Cite

Polyamidoamine (PAMAM) dendrimers, with their unique structural versatility and tunable surface functionalities, have emerged as promising nanomaterials for a wide range of biomedical applications. However, their in vivo use raises concerns, as unintended interactions between dendrimers and blood components could disrupt the delicate hemostatic balance and lead to serious complications like bleeding or thrombosis. In this study, we explored the impact of low-generation PAMAM dendrimers on the kinetics of fibrin clot formation, along with their influence on the structure, properties, and resistance to lysis of the resulting clots. For this purpose, we employed a multilevel characterization approach using purified fibrinogen, human plasma, and whole blood to assess the effects of four dendrimer types: G2-NH 2 , G4-NH 2 , G3.5-COOH, and G4-OH. Among the main findings, both G2-NH 2 and G4-NH 2 significantly impaired thrombin generation and delayed clot formation, with G4-NH 2 also promoting fibrin aggregation, increasing clot permeability, and accelerating clot lysis. When present at high concentrations, G4-OH also affected critical clotting parameters, delaying thrombin generation and prolonging clotting time. Notably, the prolongation of clotting time by G4-OH was evident in both human plasma and whole blood. Interestingly, G3.5-COOH showed potential as a safer option since it induced minimal alterations across most tested metrics. These results will be important for guiding the rational design of dendrimers and identifying safe concentrations for future clinical applications.

show abstract

In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate

Cited by 4 publications

References 45 publications

Dendrimer nanoplatforms for oral drug delivery applications

Dendrimer nanoplatforms for oral drug delivery applications

Bioinspired nanomaterials: From synthesis to applications

How Dendrimers Impact Fibrin Clot Formation, Structure, and Properties

Contact Info

Product

Resources

About